Annual report pursuant to Section 13 and 15(d)


Cover - USD ($)
12 Months Ended
Jun. 30, 2022
Sep. 01, 2022
Dec. 31, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Jun. 30, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --06-30    
Entity File Number 001-40388    
Entity Registrant Name ANEBULO PHARMACEUTICALS, INC.    
Entity Central Index Key 0001815974    
Entity Tax Identification Number 85-1170950    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1415 Ranch Road 620 South    
Entity Address, Address Line Two Suite 201    
Entity Address, City or Town Lakeway    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 78734    
City Area Code (512)    
Local Phone Number 598-0931    
Title of 12(b) Security Common Stock    
Trading Symbol ANEB    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 49,681,078
Entity Common Stock, Shares Outstanding   23,368,567  
Documents Incorporated by Reference Portions of the Registrant’s definitive proxy statement (the “Proxy Statement”) that will be filed for the 2022 Annual Meeting of Stockholders are incorporated by reference in Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Annual Report relates.    
Auditor Firm ID 274    
Auditor Name EISNERAMPER LLP    
Auditor Location Iselin, New Jersey